' x='0' y='0' width='795' height='447'%3E%3C/rect%3E%3Ctext id='Loading-Preview' font-family='AvenirNext-Bold, Avenir Next' font-size='42' font-weight='bold' fill='%23FFFFFF'%3E%3Ctspan x='228.715' y='211'%3ELoading Preview%3C/tspan%3E%3C/text%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Description | Your page doesn't have meta description |
h1 tags | We see a bright future |
h2 tags | for Canada's life science industry. We are building on solid ground Working together What’s new in our community Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec adMare BioInnovations Launches the adMare Institute Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities Events you can't miss Shape the future of Canada’s life science industry with us Join a Community with reach |
Site Speed | 1.230190038681 |
Alexa Rank: |
0 |
Site's Traffic |
|
| Host | Type | Class | TTL | Target |
| admarebio.com | A | IN | 3600 | |
| admarebio.com | NS | IN | 21600 | ns1.bdm.microsoftonline.com |
| admarebio.com | NS | IN | 21600 | ns2.bdm.microsoftonline.com |
| admarebio.com | NS | IN | 21600 | ns3.bdm.microsoftonline.com |
| admarebio.com | NS | IN | 21600 | ns4.bdm.microsoftonline.com |
| admarebio.com | SOA | IN | 3600 | |
| admarebio.com | MX | IN | 3600 | admarebio-com.mail.protection.outlook.com |
| admarebio.com | TXT | IN | 1800 | |
| admarebio.com | TXT | IN | 1800 |